Answers are grounded in this paper and cite their sources.
Background Ketamine-associated cholestatic liver injury is reported in patients with severe burn injury, but its association with patient outcome is unclear. Aim We investigated the relationship between ketamine exposure, cholestatic liver injury, and outcome of critically ill burn patients. Methods In a retrospective study, severe burn injury patients were analyzed across two periods: unrestricted ketamine prescription (ketamine-liberal) and capped ketamine dosage (ketamine-restricted). The primary endpoint was cholestatic liver injury, and the secondary endpoint was 3-month mortality. Binary logistic regression models and the RECAM method were used to measure the strength of associations and causality assessment, respectively. Results Of 279 patients [median (IQR) age 51 (31, 67) years; 63.1% men; burned surface area: 28.5 (20, 45) %], 155 (56%) were in the ketamine-liberal group, and 124 (44%) in the ketamine-restricted group, with comparable clinical characteristics, except for ketamine exposure [median doses 265.0 (0-8,021) mg and 20 (0-105) mg, respectively (P<0.001)]. A dose- and time-dependent relationship was observed between ketamine exposure and cholestatic liver injury. Ketamine restriction was associated with a reduced risk of cholestatic liver injury [AOR (95% CI): 0.16 (0.04 – 0.50); P=0.003], and with a higher probability of 3-month survival (P=0.035). RECAM indicated that ketamine was probably and possibly the cause of cholestatic liver injury for 14 and 10 patients, respectively. Cholangitis was not observed in the ketamine-restricted group. In propensity-matched patients, the risk of 3-month mortality was higher [AOR 9.92 (2.76 – 39.05), P=0.001] in patients with with cholestatic liver injury and ketamine exposure ≥ 10,000 mg. Other sedative drugs were not associated with liver and patient outcome. Conclusion In this cohort, ketamine restriction was associated with less cholestatic liver injury and reduced 3-month mortality. Lay summary In a cohort of 279 critically ill burned patients, ketamine was associated with a risk of liver bile duct toxicity. The risk was found to be dependent on both the dosage and the duration of ketamine use. A restriction policy of ketamine prescription was associated with a risk-reduction of liver injury and of 3-month mortality. These findings have implications for the analgesia and the sedation of critically ill patients with ketamine, with higher doses raising safety concerns.
No takes yet. Share an insight, caveat, or question.
Tymowski et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: